Computational analysis of the genetic and environmental contributions to disease-related human phenotypes: From predicting adverse lipid response of HIV patients receiving antiretroviral therapy to genome-wide association studies of cardiovascular and lipid related disorders

Genetic variants influence the risk to develop certain diseases or give rise to differences in drug response. Recent progresses in cost-effective, high-throughput genome-wide techniques, such as microarrays measuring Single Nucleotide Polymorphisms (SNPs), have facilitated genotyping of large clinical and population cohorts. Combining the massive genotypic data with measurements of phenotypic traits allows for the determination of genetic differences that explain, at least in part, the phenotypic variations within a population. So far, models combining the most significant variants can only explain a small fraction of the variance, indicating the limitations of current models. In particular, researchers have only begun to address the possibility of interactions between genotypes and the environment. Elucidating the contributions of such interactions is a difficult task because of the large number of genetic as well as possible environmental factors.In this thesis, I worked on several projects within this context. My first and main project was the identification of possible SNP-environment interactions, where the phenotypes were serum lipid levels of patients from the Swiss HIV Cohort Study (SHCS) treated with antiretroviral therapy. Here the genotypes consisted of a limited set of SNPs in candidate genes relevant for lipid transport and metabolism. The environmental variables were the specific combinations of drugs given to each patient over the treatment period. My work explored bioinformatic and statistical approaches to relate patients' lipid responses to these SNPs, drugs and, importantly, their interactions. The goal of this project was to improve our understanding and to explore the possibility of predicting dyslipidemia, a well-known adverse drug reaction of antiretroviral therapy. Specifically, I quantified how much of the variance in lipid profiles could be explained by the host genetic variants, the administered drugs and SNP-drug interactions and assessed the predictive power of these features on lipid responses. Using cross-validation stratified by patients, we could not validate our hypothesis that models that select a subset of SNP-drug interactions in a principled way have better predictive power than the control models using "random" subsets. Nevertheless, all models tested containing SNP and/or drug terms, exhibited significant predictive power (as compared to a random predictor) and explained a sizable proportion of variance, in the patient stratified cross-validation context. Importantly, the model containing stepwise selected SNP terms showed higher capacity to predict triglyceride levels than a model containing randomly selected SNPs. Dyslipidemia is a complex trait for which many factors remain to be discovered, thus missing from the data, and possibly explaining the limitations of our analysis. In particular, the interactions of drugs with SNPs selected from the set of candidate genes likely have small effect sizes which we were unable to detect in a sample of the present size (<800 patients).In the second part of my thesis, I performed genome-wide association studies within the Cohorte Lausannoise (CoLaus). I have been involved in several international projects to identify SNPs that are associated with various traits, such as serum calcium, body mass index, two-hour glucose levels, as well as metabolic syndrome and its components. These phenotypes are all related to major human health issues, such as cardiovascular disease. I applied statistical methods to detect new variants associated with these phenotypes, contributing to the identification of new genetic loci that may lead to new insights into the genetic basis of these traits. This kind of research will lead to a better understanding of the mechanisms underlying these pathologies, a better evaluation of disease risk, the identification of new therapeutic leads and may ultimately lead to the realization of "personalized" medicine.

Reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy

Direct evidence confirming the hypothesis that a dysfunction of the mitochondrial respiratory chain (MRC) underlies the pathogenesis of hyperlactatemia associated with highly active antiretroviral therapy (HAART) is scarce. We studied mitochondrial DNA (mtDNA) content and MRC function in the skeletal muscle of an HIV-infected patient during an episode of symptomatic hyperlactatemia. Skeletal muscle biopsy was performed during the episode when the patient was symptomatic and 3 months later when the patient was clinically recovered. Assessment of mitochondria was performed using histological, polarographic, spectrophotometrical, and Southern blot and real time PCR DNA quantification methods. The histological study disclosed extensive mitochondrial impairment in the form of ragged-red fibers or equivalents on oxidative reactions. These findings were associated with an increase in mitochondrial content and a decrease in both mitochondrial respiratory capacity and MRC enzyme activities. Mitochondrial DNA content declined to 53% of control values. Mitochondrial abnormalities had almost disappeared later when the patient became asymptomatic. Our findings support the hypothesis that MRC dysfunction stands at the basis of HAART-related hyperlactatemia.

Reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy

Direct evidence confirming the hypothesis that a dysfunction of the mitochondrial respiratory chain (MRC) underlies the pathogenesis of hyperlactatemia associated with highly active antiretroviral therapy (HAART) is scarce. We studied mitochondrial DNA (mtDNA) content and MRC function in the skeletal muscle of an HIV-infected patient during an episode of symptomatic hyperlactatemia. Skeletal muscle biopsy was performed during the episode when the patient was symptomatic and 3 months later when the patient was clinically recovered. Assessment of mitochondria was performed using histological, polarographic, spectrophotometrical, and Southern blot and real time PCR DNA quantification methods. The histological study disclosed extensive mitochondrial impairment in the form of ragged-red fibers or equivalents on oxidative reactions. These findings were associated with an increase in mitochondrial content and a decrease in both mitochondrial respiratory capacity and MRC enzyme activities. Mitochondrial DNA content declined to 53% of control values. Mitochondrial abnormalities had almost disappeared later when the patient became asymptomatic. Our findings support the hypothesis that MRC dysfunction stands at the basis of HAART-related hyperlactatemia.

Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.

BACKGROUND: Cardiovascular disease and non-AIDS malignancies have become major causes of death among HIV-infected individuals. The relative impact of lifestyle and HIV-related factors are debated. METHODS: We estimated associations of smoking with mortality more than 1 year after antiretroviral therapy (ART) initiation among HIV-infected individuals enrolled in European and North American cohorts. IDUs were excluded. Causes of death were assigned using standardized procedures. We used abridged life tables to estimate life expectancies. Life-years lost to HIV were estimated by comparison with the French background population. RESULTS: Among 17 995 HIV-infected individuals followed for 79 760 person-years, the proportion of smokers was 60%. The mortality rate ratio (MRR) comparing smokers with nonsmokers was 1.94 [95% confidence interval (95% CI) 1.56-2.41]. The MRRs comparing current and previous smokers with never smokers were 1.70 (95% CI 1.23-2.34) and 0.92 (95% CI 0.64-1.34), respectively. Smokers had substantially higher mortality from cardiovascular disease, non-AIDS malignancies than nonsmokers [MRR 6.28 (95% CI 2.19-18.0) and 2.67 (95% CI 1.60-4.46), respectively]. Among 35-year-old HIV-infected men, the loss of life-years associated with smoking and HIV was 7.9 (95% CI 7.1-8.7) and 5.9 (95% CI 4.9-6.9), respectively. The life expectancy of virally suppressed, never-smokers was 43.5 years (95% CI 41.7-45.3), compared with 44.4 years among 35-year-old men in the background population. Excess MRRs/1000 person-years associated with smoking increased from 0.6 (95% CI -1.3 to 2.6) at age 35 to 43.6 (95% CI 37.9-49.3) at age at least 65 years. CONCLUSION: Well treated HIV-infected individuals may lose more life years through smoking than through HIV. Excess mortality associated with smoking increases markedly with age. Therefore, increases in smoking-related mortality can be expected as the treated HIV-infected population ages. Interventions for smoking cessation should be prioritized.

Terapia sistémica de pareja en la depresión: un estudio de caso único

En este estudio de caso único se presenta el tratamiento de una mujer diagnosticada de depresión mayor con terapia sistémica de pareja. Esta modalidad de terapia supone la inclusión de la pareja en todas las sesiones de tratamiento, en las que se trabaja con ambos de forma conjunta. A medida que avanza la terapia se van explicitando los significados relacionales de los síntomas y las dificultades de relación, y se trabaja de forma conjunta para remediarlas. El proceso terapéutico se completó con 11 sesiones, la mayoría quincenales, y los resultados de la evaluación al terminar el tratamiento mostraron un descenso notable de los síntomas depresivos de la paciente (según el BDI-II) con respecto a la evaluación inicial. Asimismo, en la entrevista diagnóstica post-tratamiento no cumplía tampoco los criterios de depresión mayor. En cuanto a la pareja, ambos percibieron la relación como más armónica (según el DAS). Dentro de las limitaciones propias de los estudios de caso único, este trabajo permite ilustrar las potencialidades del enfoque sistémico en el tratamiento de la depresión.

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

BACKGROUND: Adverse effects of combination antiretroviral therapy (CART) commonly result in treatment modification and poor adherence. METHODS: We investigated predictors of toxicity-related treatment modification during the first year of CART in 1318 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from the Swiss HIV Cohort Study who began treatment between January 1, 2005, and June 30, 2008. RESULTS: The total rate of treatment modification was 41.5 (95% confidence interval [CI], 37.6-45.8) per 100 person-years. Of these, switches or discontinuations because of drug toxicity occurred at a rate of 22.4 (95% CI, 19.5-25.6) per 100 person-years. The most frequent toxic effects were gastrointestinal tract intolerance (28.9%), hypersensitivity (18.3%), central nervous system adverse events (17.3%), and hepatic events (11.5%). In the multivariate analysis, combined zidovudine and lamivudine (hazard ratio [HR], 2.71 [95% CI, 1.95-3.83]; P < .001), nevirapine (1.95 [1.01-3.81]; P = .050), comedication for an opportunistic infection (2.24 [1.19-4.21]; P = .01), advanced age (1.21 [1.03-1.40] per 10-year increase; P = .02), female sex (1.68 [1.14-2.48]; P = .009), nonwhite ethnicity (1.71 [1.18-2.47]; P = .005), higher baseline CD4 cell count (1.19 [1.10-1.28] per 100/microL increase; P < .001), and HIV-RNA of more than 5.0 log(10) copies/mL (1.47 [1.10-1.97]; P = .009) were associated with higher rates of treatment modification. Almost 90% of individuals with treatment-limiting toxic effects were switched to a new regimen, and 85% achieved virologic suppression to less than 50 copies/mL at 12 months compared with 87% of those continuing CART (P = .56). CONCLUSIONS: Drug toxicity remains a frequent reason for treatment modification; however, it does not affect treatment success. Close monitoring and management of adverse effects and drug-drug interactions are crucial for the durability of CART.

Arte-terapia y Educación Social

Del 18 al 21 de setembre d'enguany s'ha celebrat la 7a Conferencia bianual Europea d'Art-teràpia, organitzada per ECARTE (The European Consortium for Arts Therapy Education). Aquest any, i per primera vegada, ha tingut lloc a Espanya, concretament a Madrid; hi han participat 300 persones d'arreu del món i s'han presentat a la ratlla de 150 comunicacions; una d'elles ha estat la meva, titulada 'Contribuciones del Arte-terapia a la Educación Social'. ECARTE es va crear, l'any 1991, per les universitats de Hertfordshire, Münster, Nijmegen i París. En aquests moments, la formen 30 institucions de 10 països europeus. És un consorci d'universitats i d'institucions de formació superior que té com a objectiu bàsic representar i promoure el desenvolupament de l'art-teràpia a escala europea. Inclou l'art-teràpia (o plastico-teràpia), la dansa-teràpia, el drama-teràpia i la musico-teràpia. Treballa per tal de crear llaços entre professionals i estudiants, promou la investigació, el reconeixement de la professió, dóna suport al desenvolupament acadèmic i organitza conferències internacionals per a fomentar la comunicació.

Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study.

OBJECTIVES: Gender-specific data on the outcome of combination antiretroviral therapy (cART) are a subject of controversy. We aimed to compare treatment responses between genders in a setting of equal access to cART over a 14-year period. METHODS: Analyses included treatment-naïve participants in the Swiss HIV Cohort Study starting cART between 1998 and 2011 and were restricted to patients infected by heterosexual contacts or injecting drug use, excluding men who have sex with men. RESULTS: A total of 3925 patients (1984 men and 1941 women) were included in the analysis. Women were younger and had higher CD4 cell counts and lower HIV RNA at baseline than men. Women were less likely to achieve virological suppression < 50 HIV-1 RNA copies/mL at 1 year (75.2% versus 78.1% of men; P = 0.029) and at 2 years (77.5% versus 81.1%, respectively; P = 0.008), whereas no difference between sexes was observed at 5 years (81.3% versus 80.5%, respectively; P = 0.635). The probability of virological suppression increased in both genders over time (test for trend, P < 0.001). The median increase in CD4 cell count at 1, 2 and 5 years was generally higher in women during the whole study period, but it gradually improved over time in both sexes (P < 0.001). Women also were more likely to switch or stop treatment during the first year of cART, and stops were only partly driven by pregnancy. In multivariate analysis, after adjustment for sociodemographic factors, HIV-related factors, cART and calendar period, female gender was no longer associated with lower odds of virological suppression. CONCLUSIONS: Gender inequalities in the response to cART are mainly explained by the different prevalence of socioeconomic characteristics in women compared with men.

Eficacia de la terapia y/o los ejercicios terapéuticos en pacientes con trastorno temporomandibular. Alteración cóndilo-discal posterior.

Pregunta: ¿Qué tipo de terapia manual y/o ejercicios terapéuticos son más eficaces en pacientes con trastorno temporomandibular? Objetivo: Evaluar y comparar la eficacia de la terapia manual y/o los ejercicios terapéuticos en pacientes con trastorno temporomandibular. Metodología: la presente revisión bibliográfica se centra en bases de datos Medline, Scopus, PEDro y Google Scholar. Los artículos obtenidos fueron publicados entre los años 2004 y 2014. Se incluyen un total de 12 ensayos clínicos aleatorios. La literatura consta de pacientes con trastorno temporomandibular que hayan sido intervenidos con técnicas de terapia manual y/o ejercicios terapéuticos aplicados por un fisioterapeuta. Resultados: fueron seleccionados 10 estudios de alta evidencia científica para demostrar que la terapia manual combinada con ejercicio terapéutico disminuye el dolor, aumenta la abertura de la boca y corrige la anteversión de la cabeza. Conclusiones: la terapia manual combinada con ejercicios terapéuticos es efectiva para disminuir los síntomas en pacientes con trastornos temporomandibulares.

Hematoma intramural duodenal como complicação de terapia anticoagulante com Warfarin: relato de caso e revisão da literatura

Relatamos o caso de uma paciente em terapia anticoagulante oral com Warfarin, apresentando obstrução intestinal aguda. A tomografia computadorizada revelou hematoma intramural duodenal. O tratamento baseou-se na correção das provas de coagulação e medidas expectantes. Este caso ilustra o valor da tomografia computadorizada e da abordagem conservadora nos pacientes em terapia anticoagulante com obstrução aguda do intestino delgado.

Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality

OBJECTIVE: To determine the effect of nonadherence to antiretroviral therapy (ART) on virologic failure and mortality in naive individuals starting ART. DESIGN: Prospective observational cohort study. METHODS: Eligible individuals enrolled in the Swiss HIV Cohort Study, started ART between 2003 and 2012, and provided adherence data on at least one biannual clinical visit. Adherence was defined as missed doses (none, one, two, or more than two) and percentage adherence (>95, 90-95, and <90) in the previous 4 weeks. Inverse probability weighting of marginal structural models was used to estimate the effect of nonadherence on viral failure (HIV-1 viral load >500 copies/ml) and mortality. RESULTS: Of 3150 individuals followed for a median 4.7 years, 480 (15.2%) experienced viral failure and 104 (3.3%) died, 1155 (36.6%) reported missing one dose, 414 (13.1%) two doses and, 333 (10.6%) more than two doses of ART. The risk of viral failure increased with each missed dose (one dose: hazard ratio [HR] 1.15, 95% confidence interval 0.79-1.67; two doses: 2.15, 1.31-3.53; more than two doses: 5.21, 2.96-9.18). The risk of death increased with more than two missed doses (HR 4.87, 2.21-10.73). Missing one to two doses of ART increased the risk of viral failure in those starting once-daily (HR 1.67, 1.11-2.50) compared with those starting twice-daily regimens (HR 0.99, 0.64-1.54, interaction P = 0.09). Consistent results were found for percentage adherence. CONCLUSION: Self-report of two or more missed doses of ART is associated with an increased risk of both viral failure and death. A simple adherence question helps identify patients at risk for negative clinical outcomes and offers opportunities for intervention.

Valor da varredura com iodo antes da terapia ablativa em pacientes com carcinoma de tireóide

OBJETIVO: Avaliar a relevância clínica da varredura pré-dose ablativa em pacientes com carcinoma diferenciado de tireóide. MATERIAIS E MÉTODOS: Analisamos a varredura com 131I e a tireoglobulina (Tg) sérica em hipotireoidismo antes da primeira terapia ablativa em 100 pacientes submetidos a tireoidectomia total, considerando a varredura clinicamente importante quando revelou metástases ressecáveis ou que foram tratadas com doses maiores que a inicialmente proposta (100 mCi de 131I), além dos casos sem captação e com Tg < 5 ng/ml, que não receberam radioiodoterapia. RESULTADOS: A varredura revelou captação correspondente a metástases linfonodais em dez pacientes (10%), metástases distantes em cinco (5%), apenas em leito tireoidiano em 76 (76%) e foi negativa em nove (9%), sendo clinicamente relevante (indicando cirurgia, aumento da dose ou dispensando a radioiodoterapia) em 18% dos pacientes. Nos pacientes com Tg > 10 ng/ml a varredura influenciou a conduta em 41% dos casos pela presença de metástases, e naqueles com Tg < 10 ng/ml em apenas 10%, na maioria por não receberem radioiodo. CONCLUSÃO: A varredura pré-dose ablativa fornece informacões clinicamente importantes (presença de metástases) em muitos pacientes com Tg > 10 ng/ml, sendo indicada nesta condição.

Radioterapia adjuvante no tratamento do câncer de endométrio: experiência com a associação de radio-terapia externa e braquiterapia de alta taxa de dose

OBJETIVO: Analisar, retrospectivamente, os resultados da radioterapia externa (RT) combinada a braquiterapia de alta taxa de dose (BATD), adjuvantes à cirurgia para o carcinoma de endométrio. MATERIAIS E MÉTODOS: Avaliamos 141 pacientes tratados com RT e BATD adjuvantes à cirurgia, no período de janeiro de 1993 a janeiro de 2001. RT pélvica foi realizada com dose mediana de 45 Gy, e BATD realizada na dose mediana de 24 Gy, em quatro inserções semanais de 6 Gy. A idade mediana das pacientes foi de 63 anos e a distribuição por estádio clínico (EC) foi: EC I (FIGO), 52,4%; EC II, 13,5%; EC III, 29,8%; EC IV, 4,3%. RESULTADOS: Com seguimento mediano de 53,7 meses, a sobrevida livre de doença (SLD) em cinco anos foi: EC I, 88,0%; EC II, 70,8%; EC III, 55,1%; EC IV, 50,0% (p = 0,0003). A sobrevida global em cinco anos foi: EC I, 79,6%; EC II, 74,0%; EC III, 53,6%; EC IV, 100,0% (p = 0,0062). Fatores que influíram na SLD foram grau histológico e histologia seropapilífera. Dos 33 casos que apresentaram recidiva da doença, em 13 (9,2%) esta ocorreu na pelve, vagina ou cúpula vaginal. RT + BATD do fundo vaginal permitiram o controle da doença em 90,8% dos casos. CONCLUSÃO: A RT exerce papel fundamental no controle loco-regional do câncer de endométrio e permite excelentes taxas de cura nos estádios iniciais. Para os estádios mais avançados, a falha terapêutica tende a ser a distância, sugerindo a necessidade de complementação terapêutica sistêmica, com introdução de novas modalidades de tratamento, em particular a quimioterapia.

Eficacia del kinesiotape como terapia complementaria en niños que presentan espasticidad.

¿Se obtiene una mejora de resultados añadiendo Kinesiotape a sujetos que presentan PCI espástica comparado con un tratamiento convencional de fisioterapia? Objetivos: Evaluar la efectividad del Kinesiotape en cuanto a disminución de espasticidad y tono muscular, mejora de calidad de vida y aumento del rango articular. Material y métodos: se buscará una muestra de 238 sujetos con PCI espástica entre 5 y 20 años y que presenten una sinergia flexora en extremidad superior. Como criterios de exclusión se consideran: cualquier contraindicación del Kinesiotape, intervención quirúrgica de extremidad superior, consumo de neurotoxinas, bloqueantes nerviosos con agentes neurolíticos, relajantes musculares y pacientes que hayan sido tratados mediante Toxina Botulínica en extremidad superior. Los sujetos serán aleatoriamente distribuidos en dos grupos; un grupo control (n = 119) el cual realiza tratamiento específico de Bobath y un grupo experimental (n = 119) el cual realiza el tratamiento específico de Bobath añadiendo el Kinesiotape en la musculatura del bíceps braquial. Esta intervención durará ocho semanas y se reevaluarán los resultados en un periodo de seis meses y a los doce meses. Para ello se utilizaran las siguientes escalas: para la espasticidad se utilizarán las escalas de Tardieu - Held y la de Aswhorth modificada. Para medir la independencia del niño se emplearán la escala Pediatric Evaluation of Disability Inventory (PEDI), para conocer el rango articular se utilizarán un goniómetro de brazos y para determinar la actividad eléctrica del tono muscular la electromiografía (EMG).

Efecto de las diferentes duraciones de tratamiento en la terapia de movimiento inducido por restricción: Revisión bibliográfica.

Pregunta de revisión: ¿Son más eficientes las diferentes duraciones del tratamiento y de frecuencia de la terapia de movimiento inducido por restricción (TIMR) en los resultados de la actividad y de participación en los pacientes con accidente cerebrovascular crónico? Objetivo: Examinar el efecto de diferentes duraciones de tratamiento de la TIMR y la terapia de movimiento inducido por restricción modificada (TIMRm) sobre la actividad y la participación de los pacientes con accidente cerebrovascular crónico. Metodología: Se realizó una búsqueda bibliográfica en MEDLINE, CINAHL, OTSeeker, Scopus, Cochrane plus, La Biblioteca Cohrane y por búsqueda manual. Los criterios de inclusión fueron: ensayos controlados aleatorios (ECA) o cuasi-ECA con participantes de más de 18 años, accidente cerebrovascular crónico y TIMR o TIMRm en comparación con otras intervenciones. Resultados: La búsqueda final resultó en 10 ECA publicados entre 2003 y 2013. La calidad de los estudios varió en la puntuación (6-9) según la escala de PEDro. La práctica de la TIMR de 50-60 horas durante 2 semanas produjo una mejor movilidad, con evidencia moderada-alta, en comparación al tratamiento control. La TIMR durante 30 horas en tres semanas, 90 horas durante tres semanas y 15-30 horas durante 10 semanas mejora la movilidad de la extremidad superior afectada. Conclusión: La TIMR durante 30 horas en tres semanas demostró ser eficaz y eficiente en la movilidad de la mano afectada, pero se necesitan más estudios para conocer los protocolos de tratamiento óptimas para la TIMR.